Metabolic PPAR receptors and skin
Authors:
Š. Svačina
Authors‘ workplace:
III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in:
Vnitř Lék 2006; 52(5): 451-453
Category:
Diabetes and other subjects (infection, dermatovenerology and rheumatology) Hradec Králové 3 to 4 June 2005
Overview
Activators of metabolic PPAR receptors are used in diabetology and lipidology. Many substance influancing PPAR (β/δ) are in research. These substances will be perhaps used in obesitology and in atherosclerosis treatment. Much quicker is approaching the use in dermatology. The effect of receptor stimulation will be used in wound healing and in the treatment of allergic and proliferative diseases. Some realeted substancies influencing heterodimers with RXR or RAR receptors are used in the treatment of acne and skin lymfomas. Dermatology will be after internal medicine the second field where influencing of PPAR receptors will be very important.
Key words:
PPAR β (δ) - dermatology - wound healin - acne - skin allergy
Sources
1. Compe E, Egly JM. The DNA rapid/transcription factor TFIIH controls the transactivation by the peroxisome proliferator-activated receptors. Proceedings of 2nd International symposium on PPARs. Florencie: Fondazionne Giovanni Lorenzini 2003: 12.
2. Di-Poi N, Michalik L, Tan NS et al. The anti-apoptotic role of PPAR β contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 2003; 85: 257-265.
3. Haluzík M, Svačina Š. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada Publishing 2005.
4. Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 2003; 149: 229-236.
5. Pershadingh HA et al. Novel PPSR γ ligands for topical treatment of inflamamatory and proliferative diseases of skin. Proceedings of 2nd International symposium on PPARs. Florencie: Fondazionne Giovanni Lorenzini 2003: 11.
6. Ruhl R et al. Inhibition of IGE production by PPAR ligands. Proceedings of 2nd International symposium on PPARs. Florencie: Fondazionne Giovanni Lorenzini 2003: 45.
7. Shulman AI, Mangelsdorf DJ Retinoid X Receptor Heterodimers in the Metabolic syndrome. N Engl J Med 2005; 353: 604-615.
8. Smuth M et al. Differentiation and lipid accumulation in PPAR γ treated keratinocytes. Proceedings of 2nd International symposium on PPARs. Florencie: Fondazionne Giovanni Lorenzini 2003: 12.
9. Tan NS et al. Peroxisome proliferator-activated receptor (PPAR)-β as a target for wound healing drugs: what is possible? Am J Clin Dermatol 2003; 4: 523-530.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2006 Issue 5
Most read in this issue
- Diabetic skin changes from the dermatological point of view
- Glucocorticoids and diabetes mellitus
- Diffuse idiopathic skeletal hyperostosis and its relation to metabolic parameters
- Skin complications of diabetes mellitus therapy